Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Pabst

Showing results (271-280 of 332) with videos related to

Pageof 34
Sort By:
Journal of Neurointerventional Surgery|November 2, 2023
Susceptibility vessel sign, a predictor of long-term outcome in patients with stroke treated with mechanical thrombectomyMorin Beyeler, Erich Rea, Loris Weber, et al.
Blood|February 26, 2025
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 studyJoshua F Zeidner, David A Sallman, Christian Récher, et al.
Bone Marrow Transplantation|August 2, 2024
Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMTRama Al Hamed, Myriam Labopin, Depei Wu, et al.
Blood|July 19, 2013
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPARichard F Schlenk, Erdogan Taskesen, Yvette van Norden, et al.
Frontiers in Neurology|April 6, 2023
Absence of susceptibility vessel sign and hyperdense vessel sign in patients with cancer-related strokeMorin Beyeler, Lorenz Grunder, Jayan Göcmen, et al.
Frontiers in Neurology|October 2, 2025
Anticoagulant versus antiplatelet treatment for secondary stroke prevention in patients with active cancerMoritz C Kielkopf, Jayan Göcmen, Selina B Venzin, et al.
The Lancet. Haematology|November 1, 2023
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation studyThomas Pabst, Cristina Papayannidis, Fatih Demirkan, et al.
Blood Advances|February 24, 2026
MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similaritiesEmma L Boertjes, Tim Grob, Adil Al Hinai, et al.
Leukemia|June 15, 2026
Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party studySimon Renders, Maud Ngoya, Laurence de Leval, et al.
Blood Advances|January 13, 2026
MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similaritiesEmma L Boertjes, Tim Grob, Adil Salim Abdullah Al Hinai, et al.
Pageof 34

Showing results (271-280 of 332) with videos related to

Sort By:
Pageof 34
Journal of Neurointerventional Surgery|November 2, 2023
Susceptibility vessel sign, a predictor of long-term outcome in patients with stroke treated with mechanical thrombectomyMorin Beyeler, Erich Rea, Loris Weber, et al.
Blood|February 26, 2025
Magrolimab plus azacitidine vs physician's choice for untreated TP53-mutated acute myeloid leukemia: the ENHANCE-2 studyJoshua F Zeidner, David A Sallman, Christian Récher, et al.
Bone Marrow Transplantation|August 2, 2024
Allogeneic stem cell transplantation in de novo core-binding factor acute myeloid leukemia in first complete remission: data from the EBMTRama Al Hamed, Myriam Labopin, Depei Wu, et al.
Blood|July 19, 2013
The value of allogeneic and autologous hematopoietic stem cell transplantation in prognostically favorable acute myeloid leukemia with double mutant CEBPARichard F Schlenk, Erdogan Taskesen, Yvette van Norden, et al.
Frontiers in Neurology|April 6, 2023
Absence of susceptibility vessel sign and hyperdense vessel sign in patients with cancer-related strokeMorin Beyeler, Lorenz Grunder, Jayan Göcmen, et al.
Frontiers in Neurology|October 2, 2025
Anticoagulant versus antiplatelet treatment for secondary stroke prevention in patients with active cancerMoritz C Kielkopf, Jayan Göcmen, Selina B Venzin, et al.
The Lancet. Haematology|November 1, 2023
Cusatuzumab plus azacitidine in newly diagnosed acute myeloid leukaemia ineligible for intensive chemotherapy (CULMINATE): part one of a randomised, phase 2, dose optimisation studyThomas Pabst, Cristina Papayannidis, Fatih Demirkan, et al.
Blood Advances|February 24, 2026
MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similaritiesEmma L Boertjes, Tim Grob, Adil Al Hinai, et al.
Leukemia|June 15, 2026
Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party studySimon Renders, Maud Ngoya, Laurence de Leval, et al.
Blood Advances|January 13, 2026
MDS/AML and AML with myelodysplasia-related gene mutations: clinical and molecular similaritiesEmma L Boertjes, Tim Grob, Adil Salim Abdullah Al Hinai, et al.
Pageof 34